Drug intelligence / Profile preview

DGP-108

Development stage: Preclinical
Lead developer: Deargen

Overview

DGP-108 is a preclinical oncology drug discovery program from Deargen for non-small cell lung cancer. Publicly available pipeline information identifies it as part of Deargen's 4D Program and places it at the Hit Discovery stage within preclinical development. No molecular target, modality, formulation, route of administration, or detailed mechanism of action has been publicly disclosed, so it is best characterized at present as an undisclosed investigational antineoplastic candidate being advanced for NSCLC.

Other names: DGP-108-Deargen-NSCLCDGP108-Deargen-NSCLCDGP 108-Deargen-NSCLC

Beyond the preview

Go deeper on DGP-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DGP-108.

Explore the full profile